sorafenib has been researched along with Hepatic Encephalopathy in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Cheng, J; Lei, J; Li, Y; Lu, Y; Safadi, R; Si, T; Wu, T; Yang, X; Zhang, L; Zhang, R | 1 |
| Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z | 1 |
| Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H | 1 |
| Coupe, P; Fournier, P; Gautier, S; Gerard, R; Marks, AB | 1 |
| Chang, CC; Chen, YC; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Lin, YL | 1 |
1 trial(s) available for sorafenib and Hepatic Encephalopathy
| Article | Year |
|---|---|
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Ethiodized Oil; Fatigue; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
4 other study(ies) available for sorafenib and Hepatic Encephalopathy
| Article | Year |
|---|---|
Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Phenylurea Compounds; Quinolines; Retrospective Studies; Risk Factors; Sorafenib | 2022 |
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Skin Diseases; Sorafenib | 2014 |
Sorafenib-induced hepatic encephalopathy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Hepatic Encephalopathy; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2009 |
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |